Results 141 to 150 of about 184,433 (313)

Emerging options for the treatment of melanoma – focus on ipilimumab

ImmunoTargets and Therapy, 2014
Claire Roddie, Karl S Peggs UCL Cancer Institute, Department of Hematology, London, UK Abstract: Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody.
Roddie C, Peggs KS
doaj  

Diffuse Melanosis Cutis Under Immuno‐ and Targeted Therapy

JEADV Clinical Practice
In patients with highly advanced melanoma, rarely a diffuse melanosis cutis (DMC) can be noticed. Even though the condition is generally harmless itself, it can have a significant impact on the patient's well‐being as an obvious mark of the disease.
Christiane Cussigh, Lara‐Elena Hakim‐Meibodi, Alexander H. Enk, Jessica C. Hassel   +3 more
doaj   +1 more source

ZDHHC17‐Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance

Advanced Science, EarlyView.
ZDHHC17 palmitoylates CDK4, which together with TRAF6‐mediated ubiquitination, drives cell cycle progression and immune surveillance, revealing a rational combination of CDK4 inhibitors with immune checkpoint blockers for ZDHHC17‐driven cancers. ABSTRACT Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic ...
Zekang Wang, Peipei Song, Xueji Wu, Lei Wang, Wei Xie, Pinning Feng, Chao Cheng, Jianping Guo   +7 more
wiley   +1 more source

Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor

, 2004
Melanoma is the most deadly cutaneous malignancy; its incidence has risen significantly over the last 30 years and there is no effective treatment for advanced melanoma.
Ozen, Mustafa, Ittmann, M, Medreano, EE
core   +1 more source

Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center’s decade of experience

Frontiers in Oncology
BackgroundTargeted therapies and immunotherapy are currently considered the mainstay first-line treatment for advanced BRAF-mutated melanoma. However, the impact of treatment (targeted therapy and immunotherapy) and the prognostic factors are still not ...
Chen Sun, Sofia España, Nina Richarz, Carme Solé-Blanch, Aram Boada, Anna Martinez-Cardús, Alan Chu, Zongwen Liu, Jose Luis Manzano   +8 more
doaj   +1 more source

Advanced Melanoma

Hematology/Oncology Clinics of North America, 2021
Alexandra M. Haugh, April K.S. Salama, Douglas B. Johnson   +2 more
openaire   +2 more sources

Bilateral SERS‐Microneedle Patch for Co‐Diagnosis of Diabetes Mellitus and Tuberculosis Comorbidity

Advanced Science, EarlyView.
Our study introduced a U@mP@Au‐mediated bilateral SERS‐microneedle patch for analyzing glucose levels from ISF and sensitively detecting TB biomarkers from sputum, respectively. This integrated dual‐analyte detecting platform can be used for co‐diagnosis of diabetes mellitus (DM) and tuberculosis (TB) comorbidity, which was demonstrated in ex vivo ...
Xueqin Huang, Lingzhi Chen, Jing Xu, Jiaqi Yu, Shanze Chen, Huaihong Cai, Yanguang Cong, Pinghua Sun, Jiang Pi, Lang Rao, Jierong Chen, Junxia Zheng, Haibo Zhou   +12 more
wiley   +1 more source

C-reactive protein kinetics as prognostic biomarkers in advanced melanoma treated with immune checkpoint inhibitors

C-reactive protein (CRP) kinetics has emerged as a potential biomarker for predicting treatment response and survival in various tumors treated with immune checkpoint inhibitors (ICIs). However, data on CRP kinetics in melanoma are limited.
Acar, Caner, Acar, Fatma Pinar, Sahin, Gokhan, Yuksel, Haydar Cagatay, Gunenc, Damla, Karaca, Burcak, Celebi, Gulcin   +6 more
core   +1 more source

Unaddressed Challenges in the Treatment of Cutaneous Melanoma?

Medicina
Background and Objectives: While the management of noninvasive cutaneous melanoma (CM) is typically limited to a secondary excision to reduce recurrence risk and periodic follow-up, treating patients with advanced melanoma presents ongoing challenges ...
Alessia Villani, Luca Potestio, Aimilios Lallas, Zoe Apalla, Massimiliano Scalvenzi, Fabrizio Martora   +5 more
doaj   +1 more source

Targeting PLD3 Reverses the Immunosuppressive Niche by Reprogramming Tumor‐Associated Macrophages and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin, Qiong Li, Xuemei Xu, Yuhan Wu, Yin Zhu, Jieqiong Wu, Yuan Fang, Qiubei Chen, Shuyang Wang, Jiang Yu, Yaping Ye, Hongli Jiao   +11 more
wiley   +1 more source